Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
about
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitisStatins for non-alcoholic steatohepatitisBile acids for non-alcoholic fatty liver disease and/or steatohepatitisNonalcoholic fatty liver diseaseTreatment of non-alcoholic fatty liver diseaseA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDThe role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic reviewBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesStatins in liver disease: a molehill, an iceberg, or neither?Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline.Treatment options for nonalcoholic Fatty liver diseaseManagement of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Current status of therapy in nonalcoholic Fatty liver disease.Surgical treatment of nonalcoholic fatty liver disease in severely obese patientsPathogenesis and therapeutic approaches for non-alcoholic fatty liver diseaseTreatment of non-alcoholic fatty liver disease.Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.Pathogenesis and management issues for non-alcoholic fatty liver diseaseWay back for fructose and liver metabolism: bench side to molecular insights.Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence.Dyslipidemia in patients with nonalcoholic fatty liver disease.Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Review article: diagnosis and treatment of non-alcoholic fatty liver disease.Current treatment of non-alcoholic fatty liver disease.Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk.Non-alcoholic fatty liver disease from pathogenesis to management: an update.Nonalcoholic fatty liver disease in children living in the obeseogenic society.Nonalcoholic fatty liver disease: a review and update.Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions.Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease.Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.Nonalcoholic fatty liver disease: current issues and novel treatment approaches.Pharmacologic therapy for nonalcoholic fatty liver disease in adults.Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition.Pharmacotherapy for Nonalcoholic Fatty Liver Disease.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease.
P2860
Q24201595-47D7CEFD-DE84-4EBE-BADF-29E39F283EC4Q24234628-C20814C0-D8DB-4EED-8521-09E8F36886DCQ24243149-35887F9E-6746-4E77-A9C8-C4262F9E8C60Q24555779-35777A1F-EBCE-48E0-94D1-6E78AC00B64FQ24655572-E5A41AEB-79A0-4B39-9454-68DA1F727F2AQ26752487-88D07F8A-DDFA-42AE-AB9C-E2CFEDE59032Q26825269-468765E6-59F8-48D0-969C-DBA7B0B01676Q26853571-993BF32A-4570-46DC-8DCC-C635DFFE9170Q30446668-99977894-2B0A-4ABB-AF76-0DF5D6BC9DD3Q33723738-B676A514-F2CF-4D9B-998B-6A68F296CC10Q34156317-7FD03696-FD62-49EA-8190-14B48EBCDB15Q34168532-949FED9F-E0F4-40B4-ADB5-FE7F06398786Q34408961-C28FD758-E9B4-4902-A46D-8D156590D20FQ34446294-F8EEBED5-8300-4CCA-9457-7B69B2D71814Q34449857-59A93371-1758-45D0-AC6A-C5004D709D2CQ34592654-B5101929-E001-49FF-A3C9-0E2E60866E45Q35716357-D1574A8F-BC72-4583-94AD-18C42D486293Q36179902-9231513C-0F55-4D9D-88FA-9751003534E8Q36450525-6E665507-7F30-4440-B9C4-D90FC011219AQ36470320-D9885006-501E-426E-A104-4A56B7A13533Q36747250-810CD140-43A6-4005-9D77-861DF4F3B5EFQ36845703-DFC6CD83-7D3D-4B89-AAA0-1FA452BAD199Q37137987-9B1A6D2A-524A-4E11-BE25-AA999406B459Q37183154-2EEC24F1-DEA5-4B7B-9CE6-1AF8E14512FFQ37194846-CF2E92BF-C245-4CA5-AE5B-A16004040BBEQ37530973-E25F1DFA-7573-4FF3-9CBB-6A07CF4DA4A4Q37618979-6A597275-5763-47AA-ACE1-F060091C365FQ37632281-0C0D5F5D-E0A4-4B84-9052-16E465E53EA3Q37681360-9EE430B7-37FA-4EC3-92B4-A04FBBB3B5B2Q37721436-7D33EEBC-E634-49A6-8311-4FD028CCA96AQ37768230-8F993AE9-B05A-4B5F-8D9D-E452FA9C6E2DQ37993779-BB51C3B8-7848-472B-B4AC-F3DE8389E7F0Q38074826-D26E1305-9220-4018-8746-5DB6008B48B8Q38074898-008125F4-5FEE-41AD-855A-7E8968463EE7Q38077516-2442AA72-7709-42E0-A62A-91495A1BFB92Q38195808-33C4FC9B-7FA0-4891-9BE5-DC7AD679C925Q38588344-8931D630-FD0E-4AC0-A653-698F1815A187Q38782562-75D54258-C0BE-41BF-8BAF-1184C5F484F5Q39617773-F57B90C3-86EC-4749-BFC5-065AD03FC319Q39646058-F2F70FFC-0313-4E02-8F87-D99630B1EADA
P2860
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
@en
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
@nl
type
label
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
@en
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
@nl
prefLabel
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
@en
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
@nl
P2093
P356
P1476
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
@en
P2093
Enver Dolar
Faruk Memik
Gursel Savci
Macit Gulten
Murat Kiyici
Omer Yerci
Saduman Balaban Adim
Selim Giray Nak
Selim Gurel
P304
P356
10.1155/2003/857869
P407
P577
2003-12-01T00:00:00Z